Stocktoria
Kalaris Therapeutics, Inc. KLRS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-30
Kalaris Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $30.8M | $45.0M | $133.1M | $118.9M | $120.7M |
| Operating income | -$46.2M | -$51.7M | -$199.9M | -$171.2M | -$169.8M |
| Interest expense | $1.4M | $2.7M | — | — | — |
| Income tax | $0 | $0 | -$126,000 | -$265,000 | $1.0M |
| Net income | -$43.4M | -$69.2M | -$190.4M | -$168.7M | -$172.0M |
| EPS (diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
| Operating cash flow | -$38.4M | -$20.7M | -$124.5M | -$142.1M | -$106.3M |
| Free cash flow | -$38.6M | — | — | — | -$106.3M |
| Cash & equivalents | $98.1M | $1.6M | $90.1M | $106.1M | $201.7M |
| Total assets | $121.7M | $6.2M | $190.8M | $277.1M | $286.6M |
| Total liabilities | $42.9M | $56.8M | $45.0M | $52.6M | $61.3M |
| Shareholders' equity | $78.8M | -$96.6M | -$45.0M | $224.5M | $225.3M |
Source: SEC EDGAR filings · CIK 0001754068 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.